Latest Clinical Trials News

Page 6 of 140
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026
Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.
Ada Torres
Ada Torres
28 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
Resonance Health has secured an oversubscribed $6.0 million placement to fund MRI endpoint expansion, new TrialsWest sites and development of its non-invasive liver fibrosis device. The raise lifts pro forma net cash to $7.9 million, but the most consequential project remains an investigational technology backed by a small preliminary dataset.
Victor Sage
Victor Sage
27 Oct 2026
Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
Ada Torres
Ada Torres
27 Oct 2026
Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
Ada Torres
27 Oct 2026
NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.
Ada Torres
Ada Torres
27 Oct 2026
Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.
Ada Torres
Ada Torres
27 Oct 2026
Radiopharm Theranostics has received an $8 million advance against its anticipated FY26 Australian R&D tax incentive, giving the clinical-stage company additional funding for trials and working capital. The facility carries commercial interest and must be repaid by 26 October 2027.
Victor Sage
Victor Sage
26 Oct 2026
Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.
Ada Torres
Ada Torres
26 Oct 2026
AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.
Ada Torres
Ada Torres
26 Oct 2026

Browse the archive

Full archive